19 AGs sue DeVos for delaying for-profit college rules

SHARE 19 AGs sue DeVos for delaying for-profit college rules
betsydevos031317bjpg_e1545424070727.jpg

The Trump administration has revoked an Obama-era policy intended to make sure minority students aren’t unfairly punished because of their race. Education Secretary Betsy DeVos said discipline is a matter “on which classroom teachers and local school leaders deserve and need autonomy.” | Getty Images

Democratic attorneys general in 18 states and the District of Columbia are suing Education Secretary Betsy DeVos over her decision to suspend rules meant to protect students from abuses by for-profit colleges.

The lawsuit was filed Thursday in federal court in Washington and demands implementation of borrower defense to repayment rules.

The rules aim to make schools financially responsible for fraud and forbid them from forcing students to resolve complaints outside court.

They were created under President Barack Obama’s administration and were to take effect July 1.

On June 14, DeVos announced the rules would be delayed and rewritten, saying they created “a muddled process that’s unfair to students and schools.”

Massachusetts Attorney General Maura Healey is leading the lawsuit and says DeVos’ decision is “a betrayal of her office’s responsibility and a violation of federal law.”

The Latest
Girls says the man is angry that she stood up for her mom in a disagreement about the couple’s sex and drinking habits.
Parent company Global Tetrahedron has big plans to diversify the satire news website’s revenue streams and bring back a print edition
Trout Unlimited’s Trout In The Classroom teaches young students about fish and the aquatic environment, capped by a day trip to get all wet.
Businesses and neighborhood associations in River North and nearby want the city to end the dining program because of traffic congestion, delays to first responders and other headaches caused by closing off a major street artery, a local restaurant executive writes.
High doses become routine patient care even when they make patients so ill that they skip doses or stop taking the drugs. “There’s a gap in FDA’s authority that results in patients getting excess doses of a drug at excess costs,” says Dr. Mark Ratain, a University of Chicago oncologist.